Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study to Assess Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

ClinicalTrials.gov ID: NCT02760264

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT02760264. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Nov 19, 2026, 2:58 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase IIa Open-Label, Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Exploratory Efficacy of Vamorolone in Boys With Duchenne Muscular Dystrophy (DMD)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether a new medication called vamorolone is safe and well-tolerated by boys with Duchenne muscular dystrophy (DMD) ages ≥ 4 and \< 7 years old.

Study identification

NCT ID
NCT02760264
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
ReveraGen BioPharma, Inc.
Industry
Enrollment
48 participants

Conditions and interventions

Eligibility (public fields only)

Age range
4 Years to 6 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 2016 (Type not available)
Primary completion
May 1, 2018 (Actual)
Completion
May 1, 2018 (Actual)
Last update posted
Jan 2, 2019

2016 – 2018

United States locations

U.S. sites
6
U.S. states
5
U.S. cities
6
Facility City State ZIP Site status
University of California Davis Davis California 95616 —
University of Florida Gainesville Florida 32611 —
Nemours Children's Hospital Orlando Florida 32827 —
Ann & Robert H. Lurie Children's Hospital Chicago Illinois 60611 —
Duke University Durham North Carolina 27710 —
University of Texas Southwestern Medical Center Dallas Texas 75207 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 6 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02760264, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 2, 2019 · Synced Nov 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.